Wells Fargo’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-65,067
| Closed | -$222K | – | 6809 |
|
|
2018
Q3 | $222K | Buy |
65,067
+4,396
| +7% | +$15.8K | ﹤0.01% | 4953 |
|
|
2018
Q2 | $228K | Sell |
60,671
-546
| -0.9% | -$2.66K | ﹤0.01% | 4960 |
|
|
2018
Q1 | $250K | Buy |
61,217
+3,427
| +6% | +$16K | ﹤0.01% | 4860 |
|
|
2017
Q4 | $269K | Sell |
57,790
-25,026
| -30% | -$138K | ﹤0.01% | 4812 |
|
|
2017
Q3 | $588K | Buy |
82,816
+5,640
| +7% | +$40.6K | ﹤0.01% | 4222 |
|
|
2017
Q2 | $558K | Buy |
77,176
+3,250
| +4% | +$20.3K | ﹤0.01% | 4151 |
|
|
2017
Q1 | $455K | Buy |
73,926
+12,987
| +21% | +$71.2K | ﹤0.01% | 4310 |
|
|
2016
Q4 | $358K | Buy |
60,939
+25,398
| +71% | +$139K | ﹤0.01% | 4426 |
|
|
2016
Q3 | $188K | Sell |
35,541
-4,241
| -11% | -$22.9K | ﹤0.01% | 4517 |
|
|
2016
Q2 | $264K | Sell |
39,782
-2,180
| -5% | -$12.2K | ﹤0.01% | 4258 |
|
|
2016
Q1 | $196K | Buy |
41,962
+1,443
| +4% | +$5.76K | ﹤0.01% | 4423 |
|
|
2015
Q4 | $205K | Buy |
40,519
+947
| +2% | +$4.5K | ﹤0.01% | 4447 |
|
|
2015
Q3 | $139K | Sell |
39,572
-53,235
| -57% | -$356K | ﹤0.01% | 4683 |
|
|
2015
Q2 | $926K | Buy |
92,807
+26,688
| +40% | +$286K | ﹤0.01% | 3672 |
|
|
2015
Q1 | $842K | Buy |
66,119
+9,914
| +18% | +$127K | ﹤0.01% | 3636 |
|
|
2014
Q4 | $796K | Sell |
56,205
-62,283
| -53% | -$965K | ﹤0.01% | 3654 |
|
|
2014
Q3 | $1.63M | Buy |
118,488
+891
| +0.8% | +$13.6K | ﹤0.01% | 3118 |
|
|
2014
Q2 | $1.81M | Sell |
117,597
-2,723,326
| -96% | -$38.6M | ﹤0.01% | 3068 |
|
|
2014
Q1 | $48.4M | Buy |
2,840,923
+1,201,758
| +73% | +$18.1M | 0.02% | 775 |
|
|
2013
Q4 | $21.2M | Buy |
1,639,165
+1,626,028
| +12,377% | +$19.4M | 0.01% | 1208 |
|
|
2013
Q3 | $132K | Sell |
13,137
-4,463
| -25% | -$39.7K | ﹤0.01% | 4379 |
|
|
2013
Q2 | $131K | Buy |
+17,600
| New | +$138K | ﹤0.01% | 4304 |
|
Wells Fargo's KERX Position: Q4 2018 in Review
Wells Fargo sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 65,067 shares — an estimated $222K sold.
Wells Fargo first reported a position in KERX in Q2 2013 and held it in 22 quarters. The position peaked at $48.4M in Q1 2014. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.
- Wells Fargo reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
- Wells Fargo sold 65,067 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $222K.
- Wells Fargo first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 22 quarters.
- Wells Fargo's Keryx Biopharmaceuticals Inc position peaked at $48.4M in Q1 2014.
- 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.
Based on Wells Fargo's 13F filing for Q4 2018, filed 11 Feb 2019.